University Hospitals of the Ruhr-University of Bochum

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma

Retrieved on: 
Thursday, June 9, 2022
Gemcitabine, Company, University of Duisburg-Essen, AG, Survival, Forward-looking statement, CEO, University Hospitals of the Ruhr-University of Bochum, Pancreatic neuroendocrine tumor, Hope, Ovarian cancer, University, Respiration (physiology), Ed, ST, Therapy, FDA, Development, Manuscript, GLOBE, Patient, Chemische Industrie Uithoorn, Incidence, Quality of life, Industry, Organ (anatomy), Wilms' tumor, General officer, PDX, Immortalised cell line, RECIST, Pancreas, Pharmaceutical industry, Panaveli, Cancer

BERWYN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic designed to disrupt cancer’s energy metabolism and improve quality of life for patients, today announced the publication of positive data from a preclinical study evaluating GP-2250 for the treatment of pancreatic neuroendocrine carcinoma. The manuscript titled, “New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo1,” was published in the peer-reviewed journal, Cancers. 

Key Points: 
  • Neuroendocrine carcinoma of the pancreas is an aggressive form of neuroendocrine tumors which continue to increase in incidence but not in survival rates.
  • This study was the first to evaluate the effects of GP-2250 on pancreatic neuroendocrine tumors and we are very pleased with the encouraging results demonstrated.
  • This additional analysis suggests that GP-2250 may be valuable not only in pancreatic ductal adenocarcinoma but also in pancreatic neuroendocrine tumors.
  • Panavance is initially advancing development of GP-2250 for the treatment of pancreatic ductal adenocarcinoma cancer, and has active preclinical studies in numerous other cancers including ovarian cancer.

Bionano Genomics Announces Publication of Prospective Study Demonstrating Performance Improvements from OGM in the Analysis of AML and MDS Compared to Traditional Methods

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Risk, FISH, Hospital Insurance and Diagnostic Services Act, Karyotype, Method, In situ hybridization, International Journal of Cancer, University Hospitals of the Ruhr-University of Bochum, Autism, Canadian International Council, Security (finance), Lineagen, Fluorescence, University, Annual report, ELN, Genomics, COVID-19, AML, Genome, Company, Biology, Medicine, Lymphatic system, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Adoption, Acute myeloid leukemia, OGM, SAN, Classification, Forward-looking statement, Patient, MDS, Solution, SVS, Research, Myelodysplastic syndrome, Doctor of Philosophy, Software, Medical device

The authors describe how OGM detected 31% more European Leukemia Net (ELN) and recurrent myeloid abnormalities compared to karyotyping and FISH.

Key Points: 
  • The authors describe how OGM detected 31% more European Leukemia Net (ELN) and recurrent myeloid abnormalities compared to karyotyping and FISH.
  • OGM also found abnormalities in 35% more cases than karyotyping and FISH, and in 67% of samples, the karyotype could be redefined by OGM.
  • The authors also found the cost-efficiency of using a single OGM analysis, with OGM cost comparable to two FISH probes.
  • We believe this research demonstrates the usability of OGM for analysis of AML and MDS.

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Retrieved on: 
Wednesday, September 22, 2021
MSD, Clinical trial, Nature, Molecular oncology, Merck & Co., Partnership, Research, Risk, RNA, Annual report, Pandemic, Degenerative disease, Infection, Primary sclerosing cholangitis, Security (finance), Private Securities Litigation Reform Act, Doctor of Philosophy, U.S. Securities and Exchange Commission, Patient, AnadoluJet, NHC, University Hospitals of the Ruhr-University of Bochum, Crohn's disease, MBM, Metabolism, Immune system, Merck, LLC, Program, Utah State University, Psoriasis, COVID-19, Technology, Ulcerative colitis, Human, Severe acute respiratory syndrome coronavirus 2, Drug development, Mayo Clinic, Safety, DHODH, Multiple sclerosis, DRIVE, SEC, Pharmaceutical industry, Vaccine

In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.

Key Points: 
  • In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.
  • Matthias Dobbelstein, M.D., Professor of Molecular Oncology, University Medical Center Goettingen, added, "We are proud of the results of our preclinical work.
  • We were very pleased with this license agreement with Immunic and look forward to future results with these very promising combinations."
  • Although the technology in-licensed by Immunic includes the potential combination of DHODH inhibitors with nucleoside analogues, including molnupiravir, Immunic does not have any rights to molnupiravir itself.

DGAP-News: Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Retrieved on: 
Wednesday, September 22, 2021
MSD, Combination, NEW, Clinical trial, Nature, Molecular oncology, Merck & Co., Partnership, Research, Risk, RNA, Annual report, Degenerative disease, Pandemic, Infection, Primary sclerosing cholangitis, Private Securities Litigation Reform Act, Doctor of Philosophy, U.S. Securities and Exchange Commission, Patient, NHC, Detection limit, University Hospitals of the Ruhr-University of Bochum, Crohn's disease, MBM, Metabolism, Immune system, Nucleoside, Merck, LLC, Program, Utah State University, Psoriasis, Security (finance), COVID-19, Technology, Ulcerative colitis, Human, Severe acute respiratory syndrome coronavirus 2, Drug development, Mayo Clinic, Safety, DHODH, Multiple sclerosis, DRIVE, SEC, Viral disease, Pharmaceutical industry, Vaccine, IMU-838, Immunic, Inc., IMU-838, IMMUNIC, INC.

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19- Preclinical Combination Data Suggests Extra-Ordinary Synergy Between Certain DHODH Inhibitors and Nucleoside Analogues -- Combination of IMU-838 and N4-Hydroxycytidine Reduced SARS-CoV-2 Virus Levels, Including the Delta Variant, Down to the Detection Limit -NEW YORK and GOETTINGEN, Germany, September 22, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the execution of an in-license agreement with the University Medical Center Goettingen, Germany, covering the combination of DHODH inhibitors and nucleoside analogues to treat viral infections (COVID-19 and Influenza). Terms of the agreement were not disclosed.
Preclinical research recently completed by the parties and their collaborators[1] has shown that certain DHODH inhibitors, including Immunic's lead asset, IMU-838, strongly synergize with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro. For instance, in an in vitro test system, IMU-838 alone showed an up to 99.9% reduction in viral RNA at concentrations of 5 μM, which is well within the exposure levels seen in prior clinical trials. Likewise, N4-hydroxycytidine (NHC), the active metabolite of molnupiravir[2], alone, was associated with an up to 99% reduction in viral RNA at concentrations of 100 nM. Compared to single agent activity, the combination of IMU-838 and NHC achieved an extra-ordinary reduction in viral RNA, down to the limit of detection, reducing SARS-CoV-2 RNA by up to seven log units (corresponding to 0.00001% viral RNA remaining). This powerful reduction of virus replication in vitro was demonstrated across multiple SARS-CoV-2 variants, including alpha, beta and delta, highlighting the independence of this approach to mutant virus forms. In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro. The company plans to present detailed data at an upcoming scientific conference.
"Research by the University Medical Center Goettingen and other research partners revealed a profound degree of synergy in vitro when combining certain nucleoside analogues with DHODH inhibitors, including both our lead asset IMU-838 and other of our preclinical molecules," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "Recalling IMU-838's clinical activity against COVID-19 in our phase 2 CALVID-1 trial published earlier this year, and in light of recent exacerbations in COVID-19, worldwide, we are very excited to have in-licensed this technology to incorporate into our pandemic preparedness effort. However, with the extra-ordinary wealth of activity already ongoing at the company in other programs, we intend to evaluate and pursue the best possible strategic option for this program, including potential partnership, collaboration or external funding."

Key Points: 
  • Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
    The issuer is solely responsible for the content of this announcement.
  • In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.
  • Matthias Dobbelstein, M.D., Professor of Molecular Oncology, University Medical Center Goettingen, added, "We are proud of the results of our preclinical work.
  • Although the technology in-licensed by Immunic includes the potential combination of DHODH inhibitors with nucleoside analogues, including molnupiravir, Immunic does not have any rights to molnupiravir itself.